Aberrant expression and activity of G proteins and G-protein-coupled receptors (GPCRs) are frequently associated with tumorigenesis. Recent deep sequencing studies have shown that nearly 20% of human tumours harbour mutations in GPCRs. This Analysis article reviews these findings and the indications that G proteins, GPCRs and their signalling pathways represent novel therapeutic targets for cancer prevention and treatment.
- Morgan O'Hayre
- José Vázquez-Prado
- J. Silvio Gutkind